9人民好医生 P ri CHS o o r o o 7 11 1 1 15 11 15 11 11 11 14 1 1 11 1 肩 畑 正 닫 源 丁 育 腺癌最为常见。主要病因包括幽门螺杆菌! 染、慢性胃炎、遗传因素及长期高盐饮食 等。每年11月29日是"胃癌关爱日",这 一天的设立旨在促进胃癌的知识普及,增 公众对胃癌早筛查、早诊治的意识,从而排 高公众的健康水平。那么,该如何远离胃 癌,守护"胃"健康? 中国医学科学院肿瘤医院胰胃外科主任医师 王成锋 编辑: 丁亦鑫 李轶群 设计:李轶群 ● 持续性的上腹部疼痛,尤其在进食后有饱 感。 食欲减退、暖气、反酸、恶心。 ● 不明原因的消瘦、乏力、贫血。 ● 大便潜血阻性。 ● 胃部有灼热感。 ● 当胃癌进入进展期,便血、呕吐、非特异 ● 体重减轻、持续性上腹闷痛、黄疸 (巩膜 皮肤变黄）、腹水（腹腔积液）等典型症 会逐渐显现。 人民网 0人民好医生 胃癌高危人群,筛查刻不容缓 年龄在45岁及以上,且满足以下任 意一条的人群,属于胃癌高危人群,建 议定期进行筛查。 → 长期居住在胃癌高发区,或者曾经在 高发区长期生活过。 → 幽门螺杆菌感染者。 既往患有慢性 ...

Core Viewpoint - MIRXES-B (02629.HK) has received approval from the National Medical Products Administration of China for its core product GASTROClear™, marking it as the first blood test approved for non-invasive gastric cancer screening in China [1] Product Approval - GASTROClear™ is the world's first microRNA blood test approved for early detection of gastric cancer, assessing cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] - The product was previously approved in Singapore in 2019 and received "breakthrough device" designation from the FDA in 2023 [1] Significance of Approval - The approval in China represents a significant milestone for the company, indicating a successful transition from research and development to commercialization [1] - This achievement reflects the company's long-term commitment and investment in technological innovation and large-scale clinical trials [1]

Core Insights - MIRXES-B's core product GASTROClear has received approval from the National Medical Products Administration of China for use as a non-invasive gastric cancer screening IVD product, marking a significant milestone in the company's journey from research and development to commercialization [1] - GASTROClear is the first blood test approved for gastric cancer screening in China, utilizing a microRNA-based method to assess gastric cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] Group 1 - GASTROClear is designated for screening high-risk adults aged 45-74 as defined by the "Guidelines for Screening and Early Diagnosis and Treatment of Gastric Cancer in China (2024 Edition)," potentially covering over 500 million individuals [2] - The product will be implemented in both public and private medical institutions in China as an IVD testing project, significantly expanding the company's business space in the gastric cancer screening market [2] Group 2 - The company plans to continue increasing its commercialization efforts in China, including expanding the sales team and upgrading local production capabilities [2] - There will be a focus on strengthening business development and collaboration in mainland China to promote broader adoption of the product [2]

Core Insights - MIRXES-B (02629) has received approval from the National Medical Products Administration of China for its core product GASTROClear, marking it as the first blood test approved for non-invasive gastric cancer screening in China [1] - GASTROClear is the world's first microRNA blood test approved for early detection of gastric cancer, assessing cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] - The product is expected to cover a potential population of over 500 million high-risk adults aged 45-74, as defined by the "Guidelines for Gastric Cancer Screening and Early Diagnosis and Treatment (2024 Edition)" [1] Company Strategy - The company plans to continue expanding its commercialization efforts in China, including increasing the size of its sales team and upgrading local production capabilities [2] - The company aims to strengthen its business development and collaboration efforts in mainland China to promote wider adoption of its products [2]

Core Insights - MIRXES-B's core product GASTROClear™ has received approval from the National Medical Products Administration of China for Class III medical device registration, marking it as the first blood test approved for non-invasive gastric cancer screening in China [1] - GASTROClear™ is the world's first microRNA blood test approved for early detection of gastric cancer, assessing cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] - The approval allows GASTROClear™ to be used for screening high-risk adults aged 45-74, potentially covering over 500 million people in China [1] Company Strategy - The company plans to continue expanding its commercialization efforts in China, including increasing the size of its sales team and upgrading local production capabilities [2] - The company aims to strengthen its business development and collaboration efforts in mainland China to promote wider adoption of its products [2]

Core Insights - Gastric cancer is often diagnosed at an advanced stage, with early symptoms resembling common stomach ailments, leading to a significant drop in the five-year survival rate to 30% [1] - Early diagnosis is challenging due to the discomfort associated with gastroscopy, which is often perceived as a daunting procedure, and long waiting times discourage many individuals from pursuing screening [1] Industry Challenges - The difficulty in early detection of gastric cancer is primarily attributed to the similarity of early symptoms to less severe stomach issues, resulting in delayed diagnosis [1] - The perception of gastroscopy as a "sword-swallowing" level challenge contributes to the reluctance of individuals to undergo necessary screening [1] - Long waiting times for screening procedures further exacerbate the issue, leading to a high rate of abandonment among potential patients [1]

Core Viewpoint - The introduction of the world's first AI model for gastric cancer screening, DAMO GRAPE, represents a significant advancement in early detection and intervention, potentially increasing the five-year survival rate from 35% to over 90% if cancer is detected early [3][5]. Group 1: AI Model Development and Application - The DAMO GRAPE model utilizes plain CT imaging to identify early gastric cancer lesions and has undergone large-scale clinical research involving nearly 100,000 individuals across 20 centers [3]. - The model's initial screening significantly reduces the high-risk population for gastric cancer, achieving detection rates of 24.5% and 17.7% in two regional hospitals, with approximately 40% of detected cases being asymptomatic [4]. - The AI model demonstrates a sensitivity of 85.1% and specificity of 96.8%, surpassing radiologist diagnoses by 21.8% and 14.0%, respectively, making early detection of gastric cancer via plain CT feasible [4]. Group 2: Clinical Impact and Future Plans - The AI model has shown the ability to detect gastric cancer 2 to 10 months earlier than traditional methods, as evidenced by a case where a patient was diagnosed with advanced gastric cancer that could have been identified earlier with AI monitoring [4]. - The model is being deployed in high-incidence areas for gastric cancer across the country, with plans for large-scale promotion both domestically and internationally [5].